{"entity":{"id":"nct04996875","kind":"trial","name":"(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis","aka":[],"tldr":"A phase 2 trial of Bezuclastinib in systemic mastocytosis, run by Cogent Biosciences, Inc., now recruiting.","summary":"(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis is a phase 2 interventional study registered as NCT04996875 by Cogent Biosciences, Inc., with 140 participants planned, started 2021-11-09 and due to reach its primary completion in 2025-09-19. Interventions recorded: bezuclastinib. Conditions listed: Advanced Systemic Mastocytosis (AdvSM), SM With an Associated Hematologic Neoplasm (SM-AHN), Mast Cell Leukemia (MCL), Aggressive Systemic Mastocytosis (ASM). No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04996875","url":"https://clinicaltrials.gov/study/NCT04996875"}],"tags":["ctgov-ingest"],"related":[],"cancers":["systemic-mastocytosis"],"sections":[],"technologies":[],"targets":[],"drugs":["bezuclastinib"],"companies":["cogent-biosciences"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04996875","phase":"2","setting":"A Phase 2 Open-Label, Multicenter Clinical Study of the Safety, Efficacy, Pharmacokinetic, and Pharmacodynamic Profiles of CGT9486 as a Single Agent in Patients With Advanced Systemic Mastocytosis","sponsor":"Cogent Biosciences, Inc.","enrolled":140,"outcomes":[]},"route":"/trials/nct04996875/","neighbours":{"cancer":[{"id":"systemic-mastocytosis","kind":"cancer","name":"Systemic mastocytosis","route":"/cancers/systemic-mastocytosis/"}],"drug":[{"id":"bezuclastinib","kind":"drug","name":"Bezuclastinib","route":"/drugs/bezuclastinib/"}],"company":[{"id":"cogent-biosciences","kind":"company","name":"Cogent Biosciences","route":"/companies/cogent-biosciences/"}]}}